Am J Psychiatry 160:1209-1222, July 2003
© 2003 American Psychiatric Association
Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials
Stefan Leucht, M.D.,
Thomas R.E. Barnes, M.D.,
Werner Kissling, M.D.,
Rolf R. Engel, Ph.D.,
Christoph Correll, M.D., and
John M. Kane, M.D.
OBJECTIVE: The authors performed a systematic review and meta-analysis of studies of the potential of new-generation antipsychotic drugs to improve adherence and decrease relapse rates in patients with schizophrenia. METHOD: Randomized, controlled trials comparing new-generation antipsychotic drugs with placebo and/or conventional antipsychotics were identified. Data on relapse, general treatment failure, and dropout due to adverse events were extracted and combined in a meta-analysis. RESULTS: Because few trials were available for each individual drug, the effects of new-generation antipsychotic drugs as a group were analyzed. The analysis of six placebo comparisons, involving a total of 983 patients, clearly demonstrated that new-generation antipsychotic drugs are effective for relapse prevention. Eleven studies with a total of 2,032 patients provided comparative data on relapse/treatment failure for new-generation and conventional antipsychotics. The analysis revealed that rates of relapse and overall treatment failure were modestly but significantly lower with the newer drugs. Whether this advantage was partly mediated by improved adherence to treatment remains unclear. No significant superiority in terms of fewer dropouts due to adverse events was found for the newer drugs. Furthermore, a number of methodological problems were identified. CONCLUSIONS: Overall, the currently available data suggest that new-generation antipsychotics have the potential to reduce relapse rates. Methodological issues to be addressed in future trials include the choice of comparator, use of appropriate doses, application of clinically relevant relapse criteria, monitoring of adherence, and minimization of dropouts.
This article has been cited by other articles:
|
|
|
|
 
S. M. Eack, C. G. Greeno, M. F. Pogue-Geile, C. E. Newhill, G. E. Hogarty, and M. S. Keshavan
Assessing Social-Cognitive Deficits in Schizophrenia With the Mayer-Salovey-Caruso Emotional Intelligence Test
Schizophr Bull,
July 22, 2008;
(2008)
sbn091v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Swartz, T. S. Stroup, J. P. McEvoy, S. M. Davis, R. A. Rosenheck, R. S. E. Keefe, J. K. Hsiao, and J. A. Lieberman
What CATIE Found: Results From the Schizophrenia Trial
Psychiatr Serv,
May 1, 2008;
59(5):
500 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Phillips McEnany
Psychopharmacologic Strategies and Associated Challenges in the Long-Term Treatment of Schizophrenia
Journal of the American Psychiatric Nurses Association,
November 1, 2007;
13(5_suppl):
S6 - S15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Saha, D. Chant, and J. McGrath
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Arch Gen Psychiatry,
October 1, 2007;
64(10):
1123 - 1131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Eack and C. E. Newhill
Psychiatric Symptoms and Quality of Life in Schizophrenia: A Meta-Analysis
Schizophr Bull,
September 1, 2007;
33(5):
1225 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hodgson, C. Bushe, and R. Hunter
Measurement of long-term outcomes in observational and randomised controlled trials
The British Journal of Psychiatry,
August 1, 2007;
191(50):
s78 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Claassen, W. K. Fakhoury, R. Ford, and S. Priebe
Money for medication: financial incentives to improve medication adherence in assertive outreach
Psychiatr. Bull.,
January 1, 2007;
31(1):
4 - 7.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. W Buie, M. D Oertel, and S. O Cala
Allopurinol as Adjuvant Therapy in Poorly Responsive or Treatment Refractory Schizophrenia
Ann. Pharmacother.,
December 1, 2006;
40(12):
2200 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacol,
November 1, 2006;
20(6 Suppl):
20 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1069 - 1072.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. B. Jones, T. R. E. Barnes, L. Davies, G. Dunn, H. Lloyd, K. P. Hayhurst, R. M. Murray, A. Markwick, and S. W. Lewis
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Arch Gen Psychiatry,
October 1, 2006;
63(10):
1079 - 1087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Bibliography PSYCHOPHARMACOLOGY
Focus,
September 1, 2006;
4(4):
512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad and S. Dursun
Selecting antipsychotics in schizophrenia: lessons from CATIE
J Psychopharmacol,
May 1, 2006;
20(3):
332 - 334.
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S.E. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1209 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Dursun
An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
3 - 4.
[PDF]
|
|
|
|
|
|
|
A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit, P. Braunig, and R. Medori
Long-acting risperidone in stable patients with schizoaffective disorder
J Psychopharmacol,
September 1, 2005;
19(5_suppl):
22 - 31.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W.W. FLEISCHHACKER, J. RABINOWITZ, G. KEMMLER, M. EERDEKENS, and A. MEHNERT
Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year
The British Journal of Psychiatry,
August 1, 2005;
187(2):
131 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schooler, J. Rabinowitz, M. Davidson, R. Emsley, P. D. Harvey, L. Kopala, P. D. McGorry, I. Van Hove, M. Eerdekens, W. Swyzen, et al.
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Am J Psychiatry,
May 1, 2005;
162(5):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R.E. Barnes
Why indeed?: INVITED COMMENTARY ON... WHY AREN'T DEPOT ANTIPSYCHOTICS PRESCRIBED MORE OFTEN AND WHAT CAN BE DONE ABOUT IT?
Advan. Psychiatr. Treat.,
May 1, 2005;
11(3):
211 - 213.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Psychiatr Serv,
January 1, 2005;
56(1):
85 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. LUCHINS
Typical Versus Atypical Antipsychotics
Am J Psychiatry,
October 1, 2004;
161(10):
1927 - 1927.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Keith, L. Pani, B. Nick, R. Emsley, L. San, M. Turner, R. Conley, P. Scully, P. S. Chue, and B. Lachaux
Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia
Psychiatr Serv,
September 1, 2004;
55(9):
997 - 1005.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Hogarty, S. Flesher, R. Ulrich, M. Carter, D. Greenwald, M. Pogue-Geile, M. Kechavan, S. Cooley, A. L. DiBarry, A. Garrett, et al.
Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior
Arch Gen Psychiatry,
September 1, 2004;
61(9):
866 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Gilmer, C. R. Dolder, J. P. Lacro, D. P. Folsom, L. Lindamer, P. Garcia, and D. V. Jeste
Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia
Am J Psychiatry,
April 1, 2004;
161(4):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. McIntosh and S. Lawrie
Review: new generation antipsychotic drugs may reduce relapse rates more effectively than conventional antipsychotic drugs in people with schizophrenia
Evid. Based Ment. Health,
February 1, 2004;
7(1):
14 - 14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
January 1, 2004;
9(1):
31 - 32.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted: 25 Jul 03 to 7 Nov 03
Evid. Based Nurs.,
January 1, 2004;
7(1):
e1 - 1.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
